Navigation Links
GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
Date:3/10/2011

ue to increased revenue of $7.5 million generated by our hearing loss and balance disorders  program.  We entered into a research collaboration and license agreement with Novartis in January 2010, which accounted for $3.4 million of revenue in 2010, and a development agreement related to the supply of clinical trial material related to activities under the collaboration agreement in August 2010, which accounted for $4.4 million in revenue in 2010.  The two Novartis agreements resulted in increased revenue in 2010 as compared to 2009 when the only work performed for our hearing loss and balance disorders program was performed under a grant from the University of Kansas. Partially offsetting the increased revenue associated with our hearing loss and balance disorders program is decreased revenue of $3.0 million and $2.2 million associated with our HIV and FMD programs, respectively, as compared to the prior years due to reduced work scope under each program.

Operating expenses for 2010 decreased 9% to $29.1 million from $31.9 million in 2009.  Research and development expenses decreased 15% to $20.9 million in 2010 from $24.7 million in 2009. The decrease is primarily due to lower costs related to the development of TNFerade including personnel, manufacturing costs, patient costs, and professional service costs related to our TNFerade pancreatic clinical trial, due to the termination of the clinical trial in the first quarter of 2010.  

General and administrative expenses increased 14% to $8.2 million in 2010 from $7.2 million in 2009. General and administrative expenses were higher in 2010 primarily due to higher professional service costs and facility costs, partially offset by lower depreciation costs.

Fourth Quarter 2010 ResultsFor the fourth quarter ended December 31, 2010, GenVec reported a net loss of $1.0 million, or $0.01 per share, compared with a net loss of $4.3 million, or $0.04 per share, for the comparab
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. GenVec Forms Collaboration With World-Leading Animal Health Company
2. GenVec Reports Third Quarter 2010 Financial Results
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
5. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
6. Transgenomic Reports Fourth Quarter Financial Results
7. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
8. Six-Month Prospective Multi-Center Study Reports Efficacy Rates for AMS Elevate Anterior and Apical Prolapse Repair System
9. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
10. Cardiogenesis Reports Fourth Quarter and Full Year 2010 Results
11. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015  Hill-Rom Holdings, Inc. ... Stacy Enxing Seng has been elected to its ... Executive in Residence for Covidien, as well as President ... President of Peripheral Vascular from 2010 to 2012. ... the $2.6B acquisition of ev3 Incorporated, where she was ...
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... NEW YORK , March 4, 2015 /PRNewswire/ ... orthopedic device market is the increasing elderly population, ... in a recent report from the healthcare market ... aging population coupled with other risk factors such ... orthopedic incidence worldwide. Demand for innovative product designs ...
Breaking Medicine Technology:Hill-Rom Elects Stacy Enxing Seng to its Board of Directors 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Kalorama: Growing Elderly Population Drives Orthopedic Device Market 2Kalorama: Growing Elderly Population Drives Orthopedic Device Market 3
... , , , , ... Inc. (Nasdaq: RIGL ) today announced that in the ... had failed to respond to at least one biologic treatment, the ... ACR 20, ACR 50, ACR 70 and DAS28 response rates than ...
... , G rowth ... for cardiac stem cells , ... regrow, but researchers at Children,s Hospital Boston have now laid the groundwork for ... in children with congenital heart defects. In the July 24 issue of ...
Cached Medicine Technology:R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent 8Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
(Date:3/4/2015)... Cook For Your Life (CFYL), a New ... to people touched by cancer, is launching its first ... by founder Ann Ogden, will be facilitated by Drexel ... partnership will expand the program from its base. , ... After going through her own cancer treatments, Ogden realized ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... Surrey, BC (PRWEB) March 04, 2015 ... will perform LASIK and PRK procedures at their new ... Vision Correction, Dr. Joseph King and Dr. Gabriel Chu ... ophthalmology practice in Surrey is named Fraser Valley Cataract ... facility is accredited by the College of Physicians and ...
(Date:3/4/2015)... NY (PRWEB) March 04, 2015 The ... centerfold of The San Francisco Chronicle with a circulation ... 500,000 readers. Its digital component is distributed nationally through ... of top news sites and partner outlets. To explore ... , Milorganite is composed of heat-dried microbes ...
(Date:3/4/2015)... Texas (PRWEB) March 04, 2015 ... , Endometriosis can be a painful condition ... starts spreading outside of the uterus leading to very ... their families. Endometriosis can have a terrible effect on ... It is also the most common cause of infertility ...
Breaking Medicine News(10 mins):Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3
... a discovery that may well be giving HIV health care workers ... men having a highly drug resistant form of HIV in King ... rapidly than others and is likewise more difficult to treat. ... present in the four men, all gay, who are also methamphetamine ...
... the Intensive Care Unit (ICU) and family members of ... and depression in the family members, according to a ... of the New England Journal of Medicine. ... Institute of Nursing Research (NINR), a component of the ...
... impairment that strikes in the early stages of prion diseases such ... ,The findings suggest there may be a way to cure ... before it has time to kill off large numbers of brain ... lives of 158 people in Britain, and seven more are known ...
... women’s menstrual cycles affect the responsiveness of their brains’ ... of// Mental Health (NIMH), a component of the National ... ,While women were winning rewards, their circuitry was more ... ovulation and dominated by estrogen, compared to a phase ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... grant product patent for Glivec, the cancer drug from Novartis ... not be able to conduct// their drug research here in ... its research now. ,While talking ... of Novartis reveals that this decision by the Indian government ...
Cached Medicine News:Health News:Communication in the ICU to Be Strengthened 2Health News:Communication in the ICU to Be Strengthened 3Health News:Researchers Make Strides in VCJD Detection 2Health News:NIMH Studies Woman’s Hormonal Cycl 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2
... stents that save inventory, shelf space, and ... lengths from 22 cm to 28 cm. ... to glide over any guidewire and through ... ease of placement and patient comfort in ...
... internal drainage from the ureteropelvic junction to ... for ease of placement and patient compliance. ... for repositioning and ease of removal. AQ® ... that when activated, attracts and holds water ...
The CMV IgM enzyme immunoassay is for the qualitative detection of antibodies to cytomegalovirus. The CMV IgM assay is primarily indicated for the detection of early or recent infection....
The Shandon Sequenza uses the Shandon Coverplate system which ensures consistency and excellent staining quality. , , ,Allows the user to perform large immunostaining runs (up to 50 slides/run...
Medicine Products: